Acumen Pharma Reports Positive Trial Results Of ACU193 In Early Alzheimer’s Disease
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Monday announced positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheime
:max_bytes(150000):strip_icc():format(jpeg)/PaperworkatDesk-1a3837aec527439dbbf86d99a89611ba.jpg "2024 and 2025 Federal Income Tax Brackets, Standard Deductions, and Tax Rates")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1245836826-2b88234057c442f7bf5538ddb7f7584a.jpg "What It Would Take for the U.S. Dollar To Collapse")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1336655800-0cde652f461b4771aa45601032b5420b.jpg "Home Equity Loans and Divorce")
:max_bytes(150000):strip_icc():format(jpeg)/WhatIstheThree-YearRuleAug.262021-09d1295e78a743ecac4a31c6c042d52d.jpg "Reverse Mortgage Income Requirements")